Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: Results of a phase III, multicenter, randomized, 52-week, vehicle-controlled trial

被引：0
|
作者：
Lebwohl, Mark [1 ]
Lacour, Jean Philippe [2 ]
Liljedahl, Monika [3 ]
Lynde, Charles [3 ]
Morch, Marie [3 ]
Snel-Prento, Anja [3 ]
Thaci, Diamant [4 ]
Warren, Richard B. [5 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Hosp Nice, Dept Dermatol, Nice, France
[3] Leo Pharma, Ballerup, Denmark
[4] Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[5] Univ Manchester, Manchester, Lancs, England
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
12797
引用
收藏
页码：AB1 / AB1
页数：1
相关论文
共 48 条
  • [31] Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Philip J.
    Shaughnessy, Laura
    VanLunen, Brenda
    van der Heijde, Desiree
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S596 - S597
  • [32] Long-term Efficacy and Safety of K-924 Pitavastatin/Ezetimibe Fixed-dose Combination in Patients with Hypercholesterolemia: A Phase III, Multi-center, Open-label Trial
    Ako, Junya
    Yokote, Koutaro
    Tsujita, Kenichi
    Tanigawa, Ryohei
    Kamei, Ryo
    Suganami, Hideki
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2024, 31 (03) : 288 - 305
  • [33] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PALACE 4 PHASE 3, RANDOMIZED, CONTROLLED TRIAL
    Edwards, C.
    Wells, A.
    Adebajo, A.
    Kivitz, A.
    Bird, P.
    Shah, K.
    Hu, C.
    Stevens, R. M.
    Aelion, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 735 - 735
  • [34] Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from a phase III, randomized, controlled trial (ESTEEM 1)
    Reich, Kristian
    Griffiths, Christopher
    Leonardi, Craig
    Papp, Kim
    Kircik, Leon
    Day, Robert
    Chimenti, Sergio
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB174 - AB174
  • [35] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naive Patients: Results from a Phase 3, Randomized, Controlled Trial
    Wells, Alvin
    Adebajo, Adewale O.
    Aelion, Jacob A.
    Bird, Paul
    Kivitz, Alan
    Liote, Frederic
    Sarzi-Puttini, Piercarlo
    Hu, ChiaChi
    Stevens, Randall M.
    Edwards, Christopher J.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S680 - S680
  • [36] Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled phase 4 trial
    Liu, Lunfei
    Zhang, Chunlei
    Wang, Jinyan
    Chen, Kun
    Ding, Yangfeng
    Yan, Guofu
    Lu, Qianjin
    Li, Wei
    Fang, Hong
    Cheng, Hao
    Zhang, Jianzhong
    He, Yanling
    Zhu, Wei
    Lu, Yan
    Huang, Jinhua
    Pan, Weili
    Li, Ming
    Cao, Shuanglin
    Li, Shanshan
    Han, Xiuping
    He, Li
    Chen, Yayuan
    Zheng, Min
    EUROPEAN JOURNAL OF DERMATOLOGY, 2020, 30 (05) : 580 - 590
  • [37] Long-term efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: results from a 52-week randomized, double-blind, placebo-controlled multicentre trial
    Dogra, S.
    Krupashankar, D. S.
    Naidu, P.
    Prasanna, C. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 5 - 5
  • [38] Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled phase 4 trial
    Lunfei Liu
    Chunlei Zhang
    Jinyan Wang
    Kun Chen
    Yangfeng Ding
    Guofu Yan
    Qianjin Lu
    Wei Li
    Hong Fang
    Hao Cheng
    Jianzhong Zhang
    Yanling He
    Wei Zhu
    Yan Lu
    Jinhua Huang
    Weili Pan
    Ming Li
    Shuanglin Cao
    Shanshan Li
    Xiuping Han
    Li He
    Yayuan Chen
    Min Zheng
    European Journal of Dermatology, 2020, 30 : 580 - 590
  • [39] Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trial
    Panes, J.
    Garcia-Olmo, D.
    Van Assche, G.
    Colombel, J. -F.
    Reinisch, W.
    Baumgart, D. C.
    Nachury, M.
    Ferrante, M.
    Kazemi-Shirazi, L.
    Grimaud, J. C.
    de la Portilla, F.
    Goldin, E.
    Richard, M. P.
    Diez, M. C.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S5 - S5
  • [40] LONG-TERM (156-WEEK) EFFICACY AND SAFETY PROFILE OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE III, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 1)
    Kavanaugh, A.
    Gladman, D. D.
    Gomez-Reino, J. J.
    Hall, S.
    Lespessailles, E.
    Mease, P. J.
    Schett, G.
    McIlraith, M.
    Shah, K.
    Teng, L.
    Wollenhaupt, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 597 - 598
12345